logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Celcuity Inc.

CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedaā€¦ read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$84.01

Price

-8.11%

-$7.41

$91.42

Previous Close

$86.01

Open

Premium

52w Discount
Market Cap

$4.097b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$192.886m

-8.9%

1y CAGR

-47.5%

3y CAGR

-50.1%

5y CAGR
EPS

-$3.89

-2.9%

1y CAGR

-13.9%

3y CAGR

-10.5%

5y CAGR
Book Value

$53.525m

$410.164m

Assets

$356.639m

Liabilities

$195.579m

Debt
Debt to Assets

47.7%

-1.2x

Debt to EBITDA
Free Cash Flow

-$172.930m

-12.6%

1y CAGR

-50.4%

3y CAGR

-50.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.